Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield NM Drug List Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

    2026 Drug List (preferred drug formulary)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - New Mexico policy alerts

    Know when Blue Cross Blue Shield - New Mexico releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is Blue Cross and Blue Shield's 2026 Drug List describing preferred pharmacy drugs, specialty drug guidance, tiering, and coverage considerations for members and providers. It guides prescribing, prior authorization, step therapy, and dispensing limits for covered drugs.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Drug List (preferred drug formulary)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJanuary 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization when a drug is labeled 'PA' and document indication and requested quantity to support approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6possible member payment tiers described
    PA, ST, QLauthorization/management programs noted
    ~200+drug formulations and SKUs listed
    multipleentries with Prior Authorization (PA)
    QL presentmany products have quantity limits
    SP flagspecialty designation appears

    Coverage controls and requirements

    General coverage controls

    Coverage and management controls applied to drugs listed in this formulary:

    Formulary controls: Coverage may be limited to a 30-day supply (some plans allow up to a 90-day supply for maintenance medications). Prior authorization (PA), step therapy (ST), and dispensing/quantity limits (QL) may apply and are generally noted in the Special Requirements column next to medications.30 days (typical); 90 days for some maintenance meds

    See Special Requirements column and MyPrime.com for details

    Tiering and ACA preventive coverage

    Member cost and exceptions:

    Tier placement and cost-share: Drugs are placed into up to six member payment tiers (Preferred Generic Tier 1 through Non-Preferred Specialty Tier 6). Medicines marked 'AC' in the Special Requirements column may be ACA preventive products and, when conditions are met, may have limited or $0 member cost-sharing; copay waiver or coverage exception requests for ACA preventive medicines may be submitted for review.
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Drug List (preferred drug formulary)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJanuary 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization when a drug is labeled 'PA' and document indication and requested quantity to support approval.
    SourceLink
    On This Page
    Coverage controls and requirementsDrug listings and code groupsPrior authorization, documentation, and prescribing actionsStep therapy and utilization managementSpecified quantity limits and typical suppliesAdministration site and benefit assignmentTerms and abbreviationsQuick code and drug listsContext and scope

    Tier placement may vary by benefit design; verify payment at MyPrime.com

    General coverage rules for listed drugs

    Coverage is product-specific; many high-cost agents require prior authorization and/or have quantity limits

    PA and QL conditions: Coverage for drugs labeled 'PA' and/or 'QL' in the Requirements/Limits listing is subject to prior authorization approval and adherence to the stated quantity/dispensing limits. Specialty-designated products ('SP') and other administrative codes (e.g., 'AC') are noted inline and may trigger additional handling or program requirements.

    Document lists which products are PA, QL, SP, or AC in-line; exact medical necessity criteria are not included in this section

    Initial and Ongoing Coverage Requirements

    Coverage requires meeting pharmacy prior authorization and quantity limit rules

    Femhrt coverage requirements: Prior authorization required AND quantity limit not to exceed 30 tablets per 30 days for norethindrone acetate-ethinyl estradiol tab 0.5 mg-2.5 mcg (Femhrt low dose).30 tablets/30 days

    Prescriptions exceeding the QL require justification documented in the prior authorization request

    Non–FDA-approved drugs, repackaged medications, and some compounded medications are not covered under the pharmacy benefit. The document states that repackaged versions of medications already available on the market and drugs that have not received FDA approval are not covered, and that compounded medications may not be covered depending on the member's benefit plan. Providers and billing staff should verify coverage with the member's benefit materials or by calling the number on the member ID card when dispensing or billing these products.

    Medications that must be administered by a health care professional (for example, injectables given in an office, infusion center, or hospital) are generally not covered under the pharmacy benefit and may be billed to the medical benefit instead. The policy instructs providers to check the benefit design and contact the number on the member ID card if a drug is not found on the drug list or if administration setting may affect coverage.

    This segment contains no explicit clinical exclusions. The document does not list any medications or clinical scenarios that are declared excluded for clinical reasons within the provided excerpt.

    There are no explicit statements in this segment labeling any therapy as 'not medically necessary.' The excerpt provided does not include NMN language or determinations of medical necessity stated in those terms.

    Drug listings and code groups

    Listed antibiotics and formulationsmixedCovered
    amoxicillin 250 mg, 500 mg (capsules)amoxicillin (trihydrate) cap 250 mg, 500 mg
    amoxicillin suspensionsamoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml
    amoxicillin tabletsamoxicillin (trihydrate) tab 500 mg, 875 mg
    amoxicillin-clavulanate suspensions and tabletsamoxicillin & k clavulanate for susp 250-62.5 mg/5ml, 600-42.9 mg/5ml; tab 250-125 mg, 500-125 mg, 875-125 mg (Augmentin/es-600)
    ampicillin cap 500 mgampicillin cap 500 mg
    dicloxacillin capsulesdicloxacillin sodium cap 250 mg, 500 mg
    cephalosporins list (examples)cefadroxil, cefdinir, cefixime, cefpodoxime proxetil, cefprozil, cefuroxime axetil, cephalexin (various strengths and forms listed)
    Listed drugs and formulationsmixed
    NDC-like/formulation entriesExtensive list of product formulations and strengths (e.g., amoxicillin trihydrate cap 250 mg, 500 mg; azithromycin tab 250 mg, 500 mg; fidaxomicin 200 mg; fluconazole tab 50 mg, 100 mg, etc.) as listed in document.
    Drug listing (no procedural/diagnosis codes)mixed
    no CPT/HCPCS/ICD-10 codes presentDocument section lists drug names, strengths, and requirement tags (PA, QL, SP) rather than procedure or diagnosis codes.
    Listed drugs (Entocort EC)NDC | mixed
    budesonide delayed release particles cap 3 mgEntocort EC (listed repeatedly in the Requirements/Limits section)
    Listed drugs (testosterone topical products and estrogen patch)NDC | mixed
    testosterone td gel 12.5 mg/act (1%)Androgel pump
    testosterone td gel 20.25 mg/act (1.62%)Androgel pump
    testosterone td soln 30 mg/actAxiron
    ESTROGENS COMBIPATCH - estradiol-norethindronecombination transdermal patch; dosing ranges noted (0.05-0.14 mg/day, 0.05-0.25 mg/day)
    NDC / Drug listingNDC
    norethindrone acetate-ethinyl estradiol tab 0.5 mg-2.5 mcgFemhrt low dose (drug name and strength as listed)
    Examples of quantity limit thresholds
    Azithromycin (tablets)QL (60 tablets/180 days)
    Clarithromycin (ER 500 mg)QL (28 tablets/28 days)
    EPCLUSA (sofosbuvir-velpatasvir)PA, QL (28 tablets/28 days)
    ISENTRESS (raltegravir)QL (e.g., 180 tablets/30 days or 60 packets/30 days depending on formulation)
    estradiol-norethindrone combipatch daily dose range
    Combipatch daily dose range (example lines)0.05–0.14 mg/day and 0.05–0.25 mg/day listed for estradiol‑norethindrone combipatch
    Document appearanceDose ranges repeated in Requirements/Limits entries for ESTROGENS COMBIPATCH
    Associated productsListed alongside testosterone topical products and Axiron in the same Requirements/Limits section
    estradiol-norethindrone dose range
    Estradiol‑norethindrone patch dose range0.05–0.25 mg/day
    Duavee (related listing)0.05–0.25 mg/day also noted for conjugated estrogens/bazedoxifene context
    Activella exampleestradiol & norethindrone acetate tablet strengths shown (examples) in same section
    Axiron strength
    Axiron strength30 mg per actuation (30 mg/act)
    Product listingtestosterone topical solution 30 mg/act (Axiron) appears in Requirements/Limits section
    Associated managementAxiron is shown with PA and a QL of 2 bottles/30 days in the listing
    Patch quantity limit
    Patch quantity limit (Combipatch / Climara)QL: 30 patches per 30 days
    Climara strengths notedClimara patches (0.05, 0.06, 0.075, 0.1 mg/24hr) subject to QL (30 patches/30 days)
    Documentation noteRequests exceeding the listed QL for patches may require supporting documentation or prior authorization

    Prior authorization, documentation, and prescribing actions

    Prior Authorization

    Obtain Prior Authorization for PA‑flagged drugs

    Prescribers must submit a prior authorization (PA) request when a drug is flagged 'PA' in the Special Requirements column; coverage requires approval before the medication will be paid under the pharmacy benefit.

    • PA is generally noted next to medications when commonly required.
    Prior Authorization

    PA required for select high‑cost agents

    Certain high‑cost antiviral, antifungal, antimycobacterial, and antineoplastic agents are labeled PA and require prior authorization before coverage will be provided.

    • Examples include posaconazole, bedaquiline, EPCLUSA (sofosbuvir‑velpatasvir), HARVONI, and multiple oncology agents listed with 'PA'.
    Prior Authorization

    PA required for specialty oral oncology agents

    Many specialty oral oncology agents are designated PA (often alongside QL and SP); prescribers must obtain prior authorization for these products prior to dispensing.

    • Examples include palbociclib (IBRANCE), imatinib (Gleevec), ibrutinib (IMBRUVICA), lenvatinib, and multiple other oncology oral agents listed with PA and SP.
    Prior Authorization

    PA required where shown with QL (example: 10 mls/28 days)

    Some listed products show both a quantity limit and 'PA' (example entry adjacent to QL (10 mls/28 days) and PA); obtain PA when PA is indicated and adhere to the specified QL.

    • If requesting quantities beyond the QL, submit justification within the PA request.
    Note

    PA not specified for every entry in this excerpt

    The 'Requirements/Limits' fragment lists products and dose ranges but does not provide an explicit PA workflow for every item; follow Special Requirements column and benefit materials for PA specifics.

    • Refer to the Special Requirements column and member benefit materials for whether PA is required for a specific product.
    Prior Authorization

    Axiron: PA required and QL = 2 bottles/30 days

    Testosterone topical solution (Axiron) is listed with PA and a quantity limit; prior authorization documentation must be submitted and claims should reflect the QL of 2 bottles per 30 days.

    • Axiron strength listed as 30 mg/act; QL = 2 bottles/30 days.
    Note

    Follow product‑specific PA and QL listings

    The Requirements/Limits entries list product‑specific QL and PA indicators for topical testosterone and estrogen patch products; providers must follow those product limits when submitting claims or PA requests.

    • Examples include Axiron (30 mg/act) and estradiol‑norethindrone patch dose ranges (0.05–0.25 mg/day).
    Prior Authorization

    Submit PA and respect QL when both are required

    Where a product line shows 'PA, QL' (for example Axiron), providers must both obtain prior authorization and adhere to the listed quantity limit when filling the prescription.

    • Claims should match the documented QL (e.g., 2 bottles/30 days) or include PA justification for excess.
    Prior Authorization

    Obtain PA when shown next to QL

    Prior authorization is indicated alongside quantity limits in multiple listings; obtain PA when 'PA' appears next to the product or QL before dispensing.

    • Listings show 'PA' next to QL entries (e.g., QL (10 mls/28 days) PA).
    Note

    Formulary limits listed; PA criteria not detailed here

    The document lists formulary entries and Requirements/Limits for products (e.g., Axiron and estrogen combipatch) but does not provide explicit clinical PA criteria in this segment; consult the payer or MyPrime for detailed PA criteria.

    • Formulary lines include dose ranges and QLs but lack full medical necessity criteria in the excerpt.
    Billing Rule

    QL = 30 patches/30 days for estrogen combipatch

    A quantity limit of 30 patches per 30 days is specified for the estradiol‑norethindrone combination patch (Combipatch); claims exceeding this QL may be subject to denial without PA or supporting documentation.

    • Combipatch listed with QL (30 patches/30 days).
    Billing Rule

    Climara patches: QL 30 patches/30 days

    Certain Climara transdermal estradiol patch strengths are subject to a quantity limit of 30 patches per 30 days; ensure prescribed days' supply and strength align with the QL when submitting claims or PA requests.

    • Climara strengths listed (0.05, 0.06, 0.075, 0.1 mg/24hr) with QL = 30 patches/30 days.
    Prior Authorization

    PA may be required for requests exceeding QL

    When requesting quantities beyond listed QLs (for example >30 patches/30 days), prior authorization may be required; submit documentation that supports the requested quantity.

    • The policy notes prior authorization may be required if requesting quantities beyond the listed QL.
    Prior Authorization

    Femhrt low dose: PA required and QL 30/30 days

    Femhrt (norethindrone acetate‑ethinyl estradiol 0.5 mg‑2.5 mcg) is listed as PA with a quantity limit of 30 tablets per 30 days; a lack of approved PA will result in denial of coverage for this product.

    • Requirements/Limits: PA, QL (30 tablets/30 days) for Femhrt low dose.
    Documentation Required

    Resubmit PA documentation for Femhrt (duplicate entry)

    Femhrt low dose is repeated in the listing with PA and QL (30 tablets/30 days); providers must submit PA documentation for coverage and ensure claim quantity does not exceed the QL without justification.

    • Failure to obtain PA will result in denial for Femhrt low dose.
    Step Therapy

    Follow Step Therapy when 'ST' is indicated

    Step therapy (ST) may be required for some products; if an ST is noted it will appear as 'ST' in the Special Requirements column and the member may need to try a specified alternative first.

    • Refer to the Special Requirements column for an 'ST' designation and to member benefit materials for ST specifics.
    Note

    Observe 'AC' / program codes and follow listed conditions

    Some products are marked with administrative/approval codes (e.g., 'AC' or 'AC, QL') indicating additional coverage conditions; check the Special Requirements column and benefit materials for required actions.

    • AC entries may relate to ACA preventive coverage or special cost‑sharing rules; follow instruction to submit copay waiver/coverage exception as applicable.
    Note

    No explicit provider actions in this placeholder

    No additional provider actions are specified in this empty placeholder section of the excerpt.

    Note

    Consult PROVIDER ACTIONS fragments for PA/QL details

    Providers should review the PROVIDER ACTIONS fragments in the policy for specific PA/QL instructions applicable to each drug line when preparing claims or prior authorization requests.

    Step Therapy

    No ST specified unless marked 'ST'

    No explicit step therapy requirements are detailed in many parts of this excerpt; if ST applies it will be noted with 'ST' next to the medication in the Special Requirements column.

    • When ST is present, the member may need to try a specified alternative before the target medication is covered.
    Note

    Check Special Requirements and benefit materials for required actions

    Providers must use the Special Requirements column and member benefit materials to determine whether prior authorization, quantity limits, or step therapy apply for a given prescription.

    Note

    No actions recorded

    Empty placeholder — no provider actions are recorded in this part of the excerpt.

    Step Therapy

    No step therapy sequences specified here

    No step therapy sequences are provided in this text; providers should rely on the Special Requirements column and the member's benefit plan for any ST steps.

    Note

    No provider actions in this fragment

    Empty placeholder — no provider actions in this fragment of the document.

    Prior Authorization

    Submit PA where indicated in full listing

    Fragment only — ensure to submit PA and documentation where 'PA' appears in the full Requirements/Limits listing.

    Note

    Follow QL and PA notes in Requirements/Limits

    Fragment only — follow product‑specific QL and PA notes in the Requirements/Limits table when completing prior authorizations or claims.

    Prior Authorization

    Adhere to PA and QL for specialty products

    Fragment only — adhere to PA and QL shown for listed specialty products; obtain PA prior to dispensing when 'PA' is indicated.

    Note

    No provider actions in this placeholder

    Empty placeholder — no provider actions captured here.

    Documentation Required

    Submit ACA copay waiver / coverage exception requests

    ACA preventive medicine copay waiver or coverage exception requests may be submitted by the provider using forms available at bcbs.com/provider or myprime.com; decisions will be communicated to prescriber and member.

    • Call the number on the member's ID card to request a review.
    • Use provider forms available at the listed websites.
    Documentation Required

    Document clinical need when requesting QL exceptions

    When requesting an exception to a product's quantity limit, document the clinical indication and the quantity/days' supply requested to support the exception.

    • Quantity limits are shown per product (e.g., QL (28 tablets/28 days)); include clinical rationale when requesting amounts beyond the QL.
    Billing Rule

    Submit PA and bill according to listed QL

    When a product line shows 'PA' and/or 'QL' providers must submit a prior authorization and ensure claims reflect the listed quantity limit units/duration.

    • Submit PA when indicated and bill within the QL (units and time period) shown in the listing.
    Documentation Required

    Provide documentation with PA submissions

    Documented prior authorization is required for products labeled 'PA' (the policy shows PA inline with QL in some entries); include supporting clinical documentation with the PA submission.

    • If a product shows 'PA' next to a QL, include clinical justification for the requested quantity.
    Note

    No general documentation rules unless noted

    No documentation requirements are specified in many product lines in this excerpt; where documentation is required it is noted alongside the PA/QL entries.

    Documentation Required

    Axiron PA documentation and QL must be provided

    For Axiron (testosterone topical solution), prior authorization documentation is required and the quantity limit of 2 bottles per 30 days should be reflected on the claim.

    • Axiron listed as 30 mg/act with PA, QL (2 bottles/30 days).
    Documentation Required

    Follow Requirements/Limits for documentation details

    Fragment only — follow the Requirements/Limits table for specific documentation expectations when completing PA requests.

    Billing Rule

    Ensure claims reflect documented QL (e.g., 2 bottles/30 days)

    Documented quantity limits such as '2 bottles/30 days' should be reflected in the claim; include documentation when requesting quantities above the QL.

    • Claims should align with the QL units/duration specified for the product.
    Documentation Required

    Include clinical support when submitting PA for hormone products

    When PA is indicated for testosterone topical solution or estrogen combipatch, supporting clinical documentation may be required as part of the PA review.

    • Include indication, prior therapies (if relevant), and quantity/days' supply in the PA submission.
    Note

    No provider actions in this fragment

    Empty fragment — no provider actions specified in this excerpt portion.

    Documentation Required

    Support patch quantity with dosing and days' supply

    Documentation of requested quantity for patch products may be required to demonstrate adherence to the QL (e.g., 30 patches/30 days) and to justify larger requests.

    • Provide dosing strength and intended days' supply to support the requested patch quantity.
    Documentation Required

    Align dosing strength and days' supply with patch QL

    Support patch quantity requests with documented dosing strength and intended days' supply that align with the listed strengths and the QL.

    • Climara patch strengths and QL (30 patches/30 days) are included in the listing and should be matched by the prescription and documentation.
    Documentation Required

    Include product, strength range, and QL in documentation

    Required documentation elements for patch products include product name, strength range, and the designated quantity limit; include these in PA requests or when justifying exceptions.

    • Examples: product name (Climara), strength (0.05–0.1 mg/24hr), QL (30 patches/30 days).
    Documentation Required

    Provide PA documentation for PA‑labeled products

    PA documentation is required for products labeled 'PA' in the Requirements/Limits table (for example Femhrt low dose); include necessary clinical details to support the request.

    • Failure to provide PA documentation when required will result in denial.
    Documentation Required

    Document clinical need when requesting PA for Femhrt

    Prescribers should include clinical rationale supporting the need for Femhrt low dose when submitting PA, since PA is required for coverage of this product.

    • PA and QL (30 tablets/30 days) are required for Femhrt low dose.
    Prior Authorization

    PA is required for some drugs — obtain approval before dispensing

    Prior authorization is required for certain drugs; without an approved PA the medication may not be covered under the pharmacy benefit.

    • If PA is commonly required it will be noted with 'PA' in the Special Requirements column.
    Denial Risk

    Excess dispensing beyond QL may be billed to member

    Dispensing quantities above posted quantity limits may result in the member being responsible for the full cost of the excess quantity and may trigger denial of coverage for that portion.

    • For certain controlled substances state laws may also prohibit coverage beyond dispensing limits; check benefit and state rules.
    Denial Risk

    Claims without PA for 'PA'‑flagged drugs may be denied

    Drugs explicitly flagged 'PA' in the Requirements/Limits listing require prior authorization; claims submitted without PA may be denied.

    Denial Risk

    Failure to obtain PA or SP may trigger denial

    Claims for listed drugs that require prior authorization or specialty processing (SP) may be denied if the provider fails to obtain PA or arrange required specialty handling.

    • SP designations indicate specialty pharmacy distribution/handling requirements.
    Prior Authorization

    When PA is shown with QL, secure PA and match approved quantity

    Some entries show PA adjacent to a QL (for example QL (10 mls/28 days) PA); when PA is indicated alongside a QL, obtain PA before dispensing and ensure the claim quantity matches the approved amount.

    Note

    No explicit denial triggers in every line — assume noncompliance risks

    This section lists Requirements/Limits lines but does not state explicit denial triggers for every item; providers should assume PA or QL noncompliance can lead to denial where noted.

    Prior Authorization

    Axiron requests subject to PA and QL (2 bottles/30 days)

    Requests for Axiron may be subject to prior authorization and a quantity limit of 2 bottles per 30 days; submit PA and document the requested quantity to avoid denial or member billing.

    • Axiron: PA, QL (2 bottles/30 days).
    Note

    Consult full table for product‑specific actions

    Fragment only — consult the full Requirements/Limits table for explicit provider actions and denial risks related to each product line.

    Denial Risk

    Obtain PA to avoid denials

    Failure to obtain required prior authorization may result in denial of the claim for medications that are noted as PA; obtain PA prior to dispensing to avoid denials.

    Prior Authorization

    PA required as noted in Special Requirements

    Prior authorization is required for multiple listed products; providers must follow the Special Requirements column and submit PA requests where shown.

    Note

    Refer to Requirements/Limits for actions

    Fragment only — refer to the Requirements/Limits entries for specific provider actions.

    Denial Risk

    Requests over patch QL (30/30) may be denied

    Requests exceeding the Climara/estrogen patch quantity limit (30 patches/30 days) may be denied if not supported by PA or clinical documentation.

    • Ensure documentation explains the clinical need for quantities beyond the QL.
    Billing Rule

    Climara QL enforcement — 30 patches/30 days

    Quantity limits for Climara patches are enforced at 30 patches per 30 days; bill and dispense within that limit unless an approved PA supports a larger supply.

    Denial Risk

    Exceeding QL without PA/documentation risks denial

    Exceeding a listed quantity limit (for example >30 patches per 30 days) may trigger denial of coverage for the excess quantity unless an approved PA or appropriate documentation is provided.

    Denial Risk

    PA + QL noncompliance may lead to denial

    Where products are marked 'PA' and a QL is present (e.g., Femhrt or other PA‑flagged items), requests without PA or with quantities exceeding the QL may be denied.

    Denial Risk

    Femhrt denial risk if PA not obtained

    Lack of prior authorization when required for Femhrt low dose will result in denial of coverage for that product; obtain PA and include required documentation.

    • Femhrt low dose: PA, QL (30 tablets/30 days).

    Step therapy and utilization management

    Medication / ProgramSpecial Requirements
    When step therapy is commonly required for a medication, it will generally be noted with 'ST' in the Special Requirements column.
    Refer to your benefit plan materials for details; some plans may have additional ST requirements beyond those shown.
    Medication / ProgramSpecial Requirements
    Selected antiviral agents and other products (examples in Requirements/Limits) are marked with program codes such as 'AC' indicating ACA preventive designation or other administrative codes.
    Entries such as DESCOVY and Truvada show 'AC' alongside QL (30 tablets/30 days) in the Requirements/Limits listing.
    ProductManagement Flags
    Testosterone topical products (Androgel pumps; Axiron topical solution)
    Management: PA indicated for Axiron; QL examples shown (Axiron: QL 2 bottles/30 days).
    ESTROGENS COMBIPATCH (estradiol-norethindrone ace transdermal patch)
    Management: PA indicated where shown; patch QL commonly listed as QL (30 patches/30 days) for patch products (Climara examples).
    Drug / ProductCoverage Status
    Selected high-cost antiviral, antifungal, antimycobacterial, and antineoplastic agents listed with 'PA' in Requirements/Limits
    Many specialty oral oncology agents (examples in listings) are denoted 'PA' and require prior authorization before coverage

    Specified quantity limits and typical supplies

    maintenance medications (general) — typical supply lengths
    Typical supply length (standard)30‑day supply is standard for most prescriptions
    Maintenance medicationsSome plans permit a 90‑day supply for maintenance medications (e.g., hypertension, diabetes, hyperlipidemia)
    ExceptionsCertain drugs or categories may have different limits or exclusions per benefit design; refer to plan materials
    azithromycin tablet QL example
    DrugAzithromycin tablets (250 mg, 500 mg, 600 mg)
    Quantity limitQL (60 tablets/180 days)
    Source noteListed in Requirements/Limits section as example QL threshold
    EPCLUSA QL example
    DrugEPCLUSA (sofosbuvir‑velpatasvir) — tablet/pellet pack formulations
    ManagementPA required; QL (28 tablets/28 days) or QL (28 packs/28 days) for pellet packs; may be designated SP
    ContextListed among HCV agents with PA and QL restrictions
    ISENTRESS QL example
    DrugISENTRESS (raltegravir) — chewable/tab/packet formulations
    Quantity limitsQL examples include 180 tablets/30 days (chew/tab) and 60 packets/30 days (packet for suspension)
    Listing noteRequirements/Limits section shows formulation‑specific QLs
    everolimus 2 mg QL
    Drugeverolimus (Afinitor disperz) 2 mg formulation
    Quantity limitPA, QL (60 tablets/30 days)
    SpecialtyDesignated SP in the Requirements/Limits listing
    everolimus 3 mg QL
    Drugeverolimus (Afinitor disperz) 3 mg formulation
    Quantity limitPA, QL (90 tablets/30 days)
    SpecialtyDesignated SP in the Requirements/Limits listing
    palbociclib (IBRANCE) QL
    DrugPalbociclib (IBRANCE) — caps/tabs 75/100/125 mg
    Quantity limitPA, QL (21 tablets/capsules per 28 days)
    SpecialtyDesignated SP in Requirements/Limits section
    imatinib mesylate 100 mg QL
    DrugImatinib mesylate 100 mg (Gleevec)
    Quantity limitPA, QL (90 tablets/30 days)
    SpecialtyDesignated SP in Requirements/Limits listing
    imatinib mesylate 400 mg QL
    DrugImatinib mesylate 400 mg (Gleevec)
    Quantity limitPA, QL (60 tablets/30 days)
    SpecialtyDesignated SP in Requirements/Limits listing
    ibrutinib oral suspension QL
    DrugIbrutinib oral suspension (Imbruvica) 70 mg/ml
    Quantity limitPA, QL (216 mls/30 days)
    SpecialtyDesignated SP in Requirements/Limits listing
    ibrutinib 140 mg capsule QL
    DrugIbrutinib capsules 140 mg
    Quantity limitPA, QL (90 capsules/30 days)
    SpecialtyDesignated SP in Requirements/Limits listing
    inavolisib 3 mg QL
    DrugInavolisib (ITOVEBI) 3 mg
    Quantity limitPA, QL (56 tablets/28 days)
    SpecialtyDesignated SP in listing
    inavolisib 9 mg QL
    DrugInavolisib (ITOVEBI) 9 mg
    Quantity limitPA, QL (28 tablets/28 days)
    SpecialtyDesignated SP in listing
    ribociclib 200 mg packs QL
    DrugRibociclib (KISQALI) 200 mg pack
    Quantity limitPA, QL (21 tablets/28 days)
    SpecialtyDesignated SP in listing
    lapatinib 250 mg QL
    DrugLapatinib 250 mg (Tykerb)
    Quantity limitPA, QL (180 tablets/30 days)
    SpecialtyDesignated SP in listing
    lenvatinib 10 mg pack QL
    DrugLenvatinib 10 mg daily dose pack
    Quantity limitPA, QL (30 capsules/30 days)
    SpecialtyDesignated SP in listing with multiple daily‑dose packs
    lenvatinib 12 mg pack QL
    DrugLenvatinib 12 mg daily dose pack
    Quantity limitPA, QL (90 capsules/30 days)
    SpecialtyDesignated SP in listing
    lenvatinib 14 mg pack QL
    DrugLenvatinib 14 mg daily dose pack
    Quantity limitPA, QL (60 capsules/30 days)
    SpecialtyDesignated SP in listing
    lenvatinib 18 mg pack QL
    DrugLenvatinib 18 mg daily dose pack
    Quantity limitPA, QL (90 capsules/30 days)
    SpecialtyDesignated SP in listing
    lenvatinib 24 mg pack QL
    DrugLenvatinib 24 mg daily dose pack
    Quantity limitPA, QL (90 capsules/30 days)
    SpecialtyDesignated SP in listing
    olaparib (LYNPARZA) QL
    DrugOlaparib (LYNPARZA) 100/150 mg
    Quantity limitPA, QL (120 tablets/30 days)
    SpecialtyDesignated SP in listing
    trametinib solution QL
    DrugTrametinib oral solution (MEKINIST)
    Quantity limitPA, QL (13 bottles/28 days)
    SpecialtyDesignated SP in listing
    trametinib 0.5 mg tab QL
    DrugTrametinib 0.5 mg tablet
    Quantity limitPA, QL (90 tablets/30 days)
    SpecialtyDesignated SP in listing
    nilotinib caps QL
    DrugNilotinib capsules (Tasigna)
    Quantity limitPA, QL (120 capsules/30 days)
    SpecialtyDesignated SP in listing
    darolutamide (NUBEQA) QL
    DrugDarolutamide (NUBEQA) 300 mg
    Quantity limitPA, QL (120 tablets/30 days)
    SpecialtyDesignated SP in listing
    nirogacestat 50 mg QL
    DrugNirogacestat 50 mg
    Quantity limitPA, QL (180 tablets/30 days)
    SpecialtyDesignated SP in listing
    nirogacestat 100/150 mg QL
    DrugNirogacestat 100/150 mg
    Quantity limitPA, QL (56 tablets/28 days)
    SpecialtyDesignated SP in listing
    pazopanib 200 mg QL
    DrugPazopanib 200 mg (Votrient)
    Quantity limitPA, QL (120 tablets/30 days)
    SpecialtyDesignated SP in listing
    alpelisib 200 mg pack QL
    DrugAlpelisib (PIQRAY) 200 mg pack
    Quantity limitPA, QL (28 tablets/28 days)
    SpecialtyDesignated SP in listing
    alpelisib 250/300 mg packs QL
    DrugAlpelisib 250/300 mg packs
    Quantity limitPA, QL (56 tablets/28 days)
    SpecialtyDesignated SP in listing
    pomalyst caps QL
    DrugPomalyst (pomalidomide) capsules
    Quantity limitPA, QL (21 capsules/28 days)
    SpecialtyDesignated SP in listing
    selpercatinib (RETEVMO) 40 mg QL
    DrugSelpercatinib (RETEVMO) 40 mg
    Quantity limitPA, QL (90 tablets/30 days)
    SpecialtyDesignated SP in listing
    selpercatinib 80/120/160 mg QL
    DrugSelpercatinib 80/120/160 mg
    Quantity limitPA, QL (60 tablets/30 days)
    SpecialtyDesignated SP in listing
    vimseltinib (ROMVIMZA) QL
    DrugVimseltinib (ROMVIMZA)
    Quantity limitPA, QL (8 capsules/28 days)
    SpecialtyDesignated SP in listing
    entrectinib pellet pack QL
    DrugEntrectinib pellet pack
    Quantity limitPA, QL (336 packets/28 days)
    SpecialtyDesignated SP in listing
    entrectinib caps 100 mg QL
    DrugEntrectinib capsules 100 mg
    Quantity limitPA, QL (30 capsules/30 days)
    SpecialtyDesignated SP in listing
    entrectinib caps 200 mg QL
    DrugEntrectinib capsules 200 mg
    Quantity limitPA, QL (90 capsules/30 days)
    SpecialtyDesignated SP in listing
    rucaparib (RUBRACA) QL
    DrugRucaparib (RUBRACA)
    Quantity limitPA, QL (120 tablets/30 days)
    SpecialtyDesignated SP in listing
    midostaurin (RYDAPT) QL
    DrugMidostaurin (RYDAPT) 25 mg
    Quantity limitPA, QL (240 capsules/30 days)
    SpecialtyDesignated SP in listing
    asciminib 20 mg QL
    DrugAsciminib 20 mg
    Quantity limitPA, QL (60 tablets/30 days)
    SpecialtyDesignated SP in listing
    asciminib 40 mg QL
    DrugAsciminib 40 mg
    Quantity limitPA, QL (240 tablets/30 days)
    SpecialtyDesignated SP in listing
    asciminib 100 mg QL
    DrugAsciminib 100 mg
    Quantity limitPA, QL (120 tablets/30 days)
    SpecialtyDesignated SP in listing
    sunitinib malate QL
    DrugSunitinib malate (Sutent) — various strengths
    Quantity limitPA, QL (30 or 90 capsules depending on strength)
    SpecialtyDesignated SP in listing
    capmatinib (TABRECTA) QL
    DrugCapmatinib (TABRECTA)
    Quantity limitPA, QL (112 tablets/28 days)
    SpecialtyDesignated SP in listing
    dabrafenib QL
    DrugDabrafenib (TAFINLAR)
    Quantity limitPA, QL (120 capsules/30 days)
    SpecialtyDesignated SP in listing
    osimertinib (TAGRISSO) QL
    DrugOsimertinib (TAGRISSO)
    Quantity limitPA, QL (30 tablets/30 days)
    SpecialtyDesignated SP in listing
    talazoparib (TALZENNA) QL
    DrugTalazoparib (TALZENNA)
    Quantity limitPA, QL (30 or 90 capsules depending on strength)
    SpecialtyDesignated SP in listing
    venetoclax (VENCLEXTA) QL
    DrugVenetoclax (VENCLEXTA)
    Quantity limitPA, QL (varies by strength; e.g., 60 tablets/30 days for 10 mg)
    SpecialtyDesignated SP in listing
    verzenio (abemaciclib) QL
    DrugVerzenio (abemaciclib)
    Quantity limitPA, QL (60 tablets/30 days)
    SpecialtyDesignated SP in listing
    larotrectinib solution QL
    DrugLarotrectinib oral solution
    Quantity limitPA, QL (300 mls/30 days)
    SpecialtyDesignated SP in listing
    crizotinib (XALKORI) QL
    DrugCrizotinib (XALKORI)
    Quantity limitPA, QL (up to 180 capsules depending on strength)
    SpecialtyDesignated SP in listing
    budesonide delayed release (Entocort EC) QL examples
    DrugBudesonide delayed release particles cap 3 mg (Entocort EC)
    Quantity limitsExamples show QL (10 mls/28 days) and QL (60 packets/30 days) in Requirements/Limits entries
    Listing noteEntries repeated across the Requirements/Limits section in document
    unspecified product QL 10 mls
    Unspecified liquid productQL (10 mls/28 days) shown adjacent to an unspecified product entry
    ContextAppears in Requirements/Limits listing near Entocort and topical hormone entries
    ActionRefer to specific plan listing or NDC for exact product correspondence
    unspecified packet-form product QL 60 packets
    Unspecified packet-form productQL (60 packets/30 days) shown adjacent to an unspecified packet entry
    ContextListed in Requirements/Limits section with Entocort examples
    ActionConfirm specific product/pack size on claim to apply correct QL
    ESTROGENS COMBIPATCH dose ranges
    ESTROGENS COMBIPATCH dose rangesListed dose ranges include 0.05–0.14 mg/day and 0.05–0.25 mg/day
    Associated productsAppears with Combipatch and related estrogen combination products (Duavee, Activella examples)
    Quantity guidancePatch QL entries shown elsewhere in document (e.g., 30 patches/30 days)
    Axiron QL 2 bottles
    Axiron QLQL (2 bottles/30 days)
    Product strengthTestosterone topical solution 30 mg/act (Axiron)
    Prior authorizationAxiron is listed with PA in the Requirements/Limits section
    estradiol-norethindrone patch dose range
    Estradiol‑norethindrone patch dose range0.05–0.25 mg/day (document lists 0.05–0.14 mg/day and 0.05–0.25 mg/day in various lines)
    Document contextListed in Requirements/Limits under ESTROGENS COMBIPATCH entries
    Related managementPatch QL (30 patches/30 days) shown elsewhere for patch products
    Axiron strength (duplicate) 30 mg/act
    Axiron strength (duplicate)30 mg per actuation (30 mg/act)
    ListingAppears repeatedly in Requirements/Limits section alongside estrogen patch entries
    ManagementPA and QL (2 bottles/30 days) indicated for Axiron
    unspecified topical testosterone/combipatch QL 2 bottles
    Topical testosterone / combipatch QL exampleQL (2 bottles/30 days) shown for topical testosterone entries in proximity to combipatch lines
    ContextUnspecified product lines reference 2 bottles per 30 days consistent with Axiron entries
    ActionUse exact NDC/product line to confirm which topical product the QL applies to
    unspecified product QL 2 bottles (testosterone/patch context)
    Unspecified testosterone/patch product QL2 bottles per 30 days shown for adjacent entries; likely applies to topical testosterone formulations such as Axiron
    ReferenceEntries repeated across multiple chunks indicating same QL for related product lines
    RecommendationConfirm product NDC on claim to apply the correct QL and PA requirements
    ESTROGENS COMBIPATCH QL 30
    ESTROGENS COMBIPATCH QL (patch count)QL (30 patches) — documented as 30 patches per 30 days for estradiol‑norethindrone acetate patch
    Climara QLClimara transdermal estradiol patches also listed with QL (30 patches/30 days)
    Documentation noteRequests exceeding 30 patches/30 days may require prior authorization or supporting documentation
    Climara QL 30
    Climara QLQL (30 patches/30 days)
    Strengths listedClimara strengths: 0.05, 0.06, 0.075, 0.1 mg/24hr shown in Requirements/Limits
    Related productMyfembree and other estrogen combination therapies referenced in same section
    Climara QL 30 (duplicate)
    Climara (duplicate) QL30 patches per 30 days reiterated in Requirements/Limits
    NoteListed alongside Combipatch and other estrogen products
    Provider actionDocument dosing strength and days' supply to align with QL when submitting claims or PA
    Femhrt low dose QL 30
    Femhrt low dose (norethindrone acetate‑ethinyl estradiol 0.5 mg‑2.5 mcg)QL (30 tablets/30 days); PA required
    Coverage notePrior authorization and QL shown in Requirements/Limits section
    Provider actionSubmit PA with supporting documentation when requesting Femhrt beyond QL
    Femhrt low dose QL 30 (duplicate)
    Femhrt low dose (duplicate)PA, QL (30 tablets/30 days) repeated in Requirements/Limits
    Provider reminderLack of required PA will result in denial per document guidance
    ActionFollow prior authorization and quantity documentation procedures in plan materials

    Administration site and benefit assignment

    Note

    Provider‑administered drugs may be covered under medical benefit

    Medications that must be administered by a health care professional may be covered under the medical benefit rather than the pharmacy benefit; check site‑of‑care rules for infusion/clinic‑administered drugs.

    • Provider‑administered drugs may be billed to medical benefit
    • Examples include certain injectables and chemo infusions

    Terms and abbreviations

    Specialty drugs definition
    Specialty drugs definitionMedications used for complex conditions; may be oral, topical, or injectable and can be self‑administered or provider‑administered
    Coverage noteMedications administered by a health care professional are not covered under the pharmacy benefit
    ReferenceFor current specialty list see MyPrime.com per document
    Generic equivalent vs alternative
    Generic equivalentSame active ingredient(s) at the same dosage as the reference brand (FDA‑approved)
    Generic alternativeDifferent active ingredient(s) typically used to treat the same condition
    Member cost implicationChoosing brand over an available generic may incur member cost‑share plus difference in cost
    QL definition
    DefinitionQuantity Limit (QL) — numeric limit on units allowed in a specified time period (e.g., QL (60 tablets/180 days))
    PurposeDispensing limits encourage use as intended by FDA and manage benefit costs
    Claim impactDispensed quantity exceeding QL may be billed to member with no benefits applied
    PA definition
    DefinitionPrior Authorization (PA) — payer approval required before coverage; prescriber must submit request for approval
    IndicatorPA is generally noted next to the medication in the Special Requirements column
    Denial riskClaims without required PA may be denied
    SP definition
    DefinitionSpecialty (SP) — drug designated for specialty pharmacy distribution or handling
    ContextMany oncology and high‑cost oral agents are designated SP in Requirements/Limits
    ReferenceSee MyPrime.com for current specialty medication list
    Axiron product reference
    Axiron product referenceTestosterone topical solution 30 mg/act (Axiron) listed in Requirements/Limits with PA and QL (2 bottles/30 days)
    Combipatch referenceESTROGENS COMBIPATCH (estradiol‑norethindrone acetate) dose ranges and patch QL shown in same section
    Provider actionFollow PA and QL instructions as noted in the Special Requirements column for these products
    estradiol-norethindrone patch reference
    Estradiol‑norethindrone patch referenceESTROGENS COMBIPATCH entries list dose ranges (0.05–0.14 mg/day; 0.05–0.25 mg/day) and QL (30 patches/30 days)
    AppearanceListed in Requirements/Limits alongside topical testosterone and other estrogen products
    Provider actionDocument dosing strength and days' supply to align with QL and PA when applicable
    Duavee reference
    Duavee referenceDuavee (conjugated estrogens‑bazedoxifene) dose context shown as 0.05–0.25 mg/day in Requirements/Limits
    Related entriesAppears with estradiol and norethindrone acetate product examples (Activella) in same section
    NoteDose range cited in document for related estrogen combination products
    Myfembree reference
    Myfembree referenceMyfembree (relugolix‑estradiol‑norethindrone acetate) listed at 40‑1‑0.5 mg in Requirements/Limits
    ContextListed in same section as Climara and other estrogen products with QL guidance
    Provider actionFollow product‑specific QL and PA rules where indicated

    Quick code and drug lists

    Special RequirementPresence
    ST (Step Therapy)
    PA (Prior Authorization)
    QL (Quantity Limit)
    AC (ACA preventive)
    ProductRequirements / Quantity Limit
    Testosterone td soln 30 mg/act (Axiron)
    PA required; QL: 2 bottles per 30 days (documented in Requirements/Limits).
    ESTROGENS COMBIPATCH - estradiol-norethindrone ace transdermal patch
    QL: 30 patches per 30 days (patch QL indicated); PA shown where specified in listing.
    Climara transdermal estradiol patches (examples: 0.05–0.1 mg/24hr strengths)
    QL: 30 patches per 30 days (documented QL for patch strengths).
    Norethindrone acetate-ethinyl estradiol tab 0.5 mg-2.5 mcg (Femhrt low dose)
    PA required; QL: 30 tablets per 30 days (Requirements/Limits).
    Drug (listed)NDC / Description
    norethindrone acetate-ethinyl estradiol tab 0.5 mg-2.5 mcg
    Femhrt low dose — Requirements/Limits: PA, QL (30 tablets/30 days)

    Context and scope

    Specialty drugs are therapies used to treat complex conditions such as hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis and can be oral, topical, or injectable. Many specialty agents require management controls including prior authorization (PA), quantity limits (QL), and specialty distribution (SP) designations; these controls and tier placement are used to ensure appropriate clinical use and to align benefits with FDA labeling and evidence-based guidance. Provider billing and clinical staff should note that specialty drugs administered by a health care professional may be billed to the medical benefit rather than the pharmacy benefit and that formulary-specific requirements (PA, QL, ST) are listed alongside product entries.